Your browser doesn't support javascript.
loading
Highly-Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe Polymerase Chain Reaction
Jeremy D Ratcliff; Farah Al-Beidh; Sagida Bibi; David Bonsall; Sue Ann Costa Clemens; Lise Estcourt; Amy Evans; Matthew Fish; Pedro M Folegatti; Anthony C Gordon; Cecilia Jay; Aislinn Jennings; Emma Laing; Teresa Lambe; George Macintyre-Cockett; David Menon; Paul R Mouncey; Dung Nguyen; Andrew J Pollard; Maheshi N Ramasamy; David J Roberts; Kathryn M Rowan; Jennifer Rynne; Manu Shankar-Hari; Sarah Williams; Heli Harvala; Tanya Golubchik; Peter Simmonds; - AMPHEUS Project; - REMAP-CAP Immunoglobulin Domain UK Investigators; - Oxford COVID-19 Vaccine Trial Group.
Afiliação
  • Jeremy D Ratcliff; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Farah Al-Beidh; Imperial College London, London, United Kingdom; Imperial College Health NHS Trust, St. Mary's Hospital, London, United Kingdom
  • Sagida Bibi; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom
  • David Bonsall; Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Sue Ann Costa Clemens; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom; Institute of Global Health, University of Siena, Siena, Italy
  • Lise Estcourt; Haematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Clinical Trials Unit, NHS Blood and Transport, Oxford, United
  • Amy Evans; Clinical Trials Unit, NHS Blood and Transport, Oxford, United Kingdom
  • Matthew Fish; School of Immunology and Microbial Sciences, Kings College London, London, United Kingdom; Guy's and St. Thomas' NHS Foundation Trust, St. Thomas' Hospital, Lon
  • Pedro M Folegatti; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, United Kingdom
  • Anthony C Gordon; Imperial College London, London, United Kingdom; Imperial College Health NHS Trust, St. Mary's Hospital, London, United Kingdom
  • Cecilia Jay; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Aislinn Jennings; School of Immunology and Microbial Sciences, Kings College London, London, United Kingdom; Guy's and St. Thomas' NHS Foundation Trust, St. Thomas' Hospital, Lon
  • Emma Laing; Clinical Trials Unit, NHS Blood and Transport, Oxford, United Kingdom
  • Teresa Lambe; Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, United Kingdom
  • George Macintyre-Cockett; Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • David Menon; University Division of Anaesthesia, University of Cambridge, Cambridge, United Kingdom
  • Paul R Mouncey; Intensive Care National Audit and Research Centre, London, United Kingdom
  • Dung Nguyen; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Andrew J Pollard; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom; NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
  • Maheshi N Ramasamy; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United
  • David J Roberts; Haematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Clinical, Research, and Devleopment, NHS Blood and Transport,
  • Kathryn M Rowan; Intensive Care National Audit and Research Centre, London, United Kingdom
  • Jennifer Rynne; School of Immunology and Microbial Sciences, Kings College London, London, United Kingdom; Guy's and St. Thomas' NHS Foundation Trust, St. Thomas' Hospital, Lon
  • Manu Shankar-Hari; School of Immunology and Microbial Sciences, Kings College London, London, United Kingdom; Guy's and St. Thomas' NHS Foundation Trust, St. Thomas' Hospital, Lon
  • Sarah Williams; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Oxford University Hospitals NHS Fou
  • Heli Harvala; Microbiology Services, NHS Blood and Transport, London, United Kingdom
  • Tanya Golubchik; Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Peter Simmonds; Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • - AMPHEUS Project;
  • - REMAP-CAP Immunoglobulin Domain UK Investigators;
  • - Oxford COVID-19 Vaccine Trial Group;
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21265384
ABSTRACT
IntroductionTools to detect SARS-Coronavirus-2 variants of concern and track the ongoing evolution of the virus are necessary to support public health efforts and the design and evaluation of novel COVID-19 therapeutics and vaccines. Although next-generation sequencing (NGS) has been adopted as the gold standard method for discriminating SARS-CoV-2 lineages, alternative methods may be required when processing samples with low viral loads or low RNA quality. MethodsAn allele-specific probe polymerase chain reaction (ASP-PCR) targeting lineage-specific single nucleotide polymorphisms (SNPs) was developed and used to screen 1,082 samples from two clinical trials in the United Kingdom and Brazil. Probit regression models were developed to compare ASP-PCR performance against 1,771 NGS results for the same cohorts. ResultsIndividual SNPs were shown to readily identify specific variants of concern. ASP-PCR was shown to discriminate SARS-CoV-2 lineages with a higher likelihood than NGS over a wide range of viral loads. Comparative advantage for ASP-PCR over NGS was most pronounced in samples with Ct values between 26-30 and in samples that showed evidence of degradation. Results for samples screened by ASP-PCR and NGS showed 99% concordant results. DiscussionASP-PCR is well-suited to augment but not replace NGS. The method can differentiate SARS-COV-2 lineages with high accuracy and would be best deployed to screen samples with lower viral loads or that may suffer from degradation. Future work should investigate further destabilization from primertarget base mismatch through altered oligonucleotide chemistry or chemical additives.
Licença
cc_by_nc
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Cohort_studies / Diagnostic_studies / Experimental_studies / Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Cohort_studies / Diagnostic_studies / Experimental_studies / Observational_studies / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint